Atrium Medical presents benefits of its COCTAIL research Atrium Medical Company is proud to announce the launch of the final outcomes of the COCTAIL Research, a clinical research comparing community administration of an anti-platelet medicine with the business’s proprietary infusion balloon technology. Dr. Francesco Prati of San Giovanni Medical center and the European Imaging Laboratory in Rome, Italy offered the outcomes of the study at the latest TCT meeting held in SAN FRANCISCO BAY AREA, California allergisk . Related StoriesGlan Clwyd Medical center N Wales spend money on Esaote's G-Scan MRI device for weight-bearing scanningNew UCLA research talks about primary care medical house in reducing childrens' repeat appointments to hospitalsPatients provided animal-assisted therapy at UCLA HealthThis to begin its kind coronary occlusion research is a multi-centered, randomized, single blinded, controlled medical trial comparing regional coronary administration of the medication abciximab through helpful information catheter compared with regional coronary administration of abciximab using Atrium’s novel infusion balloon catheter..
Sufferers were included if indeed they experienced occlusive lesions and disease categorized as TASC B, C, or D vessel lesions within their iliac arteries. The principal objective of COBEST would be to evaluate the outcomes great things about balloon expandable protected stent technology to today’s regular of caution with bare steel stents. This clinical research assessment included binary restenosis and independence from stent occlusion . Binary restenosis was mainly assessed through Duplex Ultrasound imaging at 6, 12, and 1. 5 years. Where a Duplex Ultrasound picture had not been obtained, stent overall performance was attained through flouroscopic exam and/or CT scan.